Hematology / Oncology @Point of Care Podcasts
76 episodes - English - Latest episode: 6 months ago -Our @Point of Care Hematology & Oncology Podcasts have healthcare experts discussing and providing information related to oncology diagnosis, treatment, management, and other important information.
Homepage Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer
December 29, 2023 18:00 - 26 minutes - 36.1 MBOur faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them. Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer
December 29, 2023 17:58 - 30 minutes - 42.4 MBIn this episode our faculty take a look at the clinical trial data on HER3-directed therapies for breast and lung cancer. Visit www.morningcommutepodcast.com/HER3Agnostic2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?
December 29, 2023 17:56 - 25 minutes - 35.2 MBIn this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar. Visit www.morningcommutepodcast.com/HER3Agnostic1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits
November 30, 2023 17:02 - 28 minutes - 38.6 MBIn this episode our faculty take a look at the ins and outs of molecular testing in patients with HR+ positive breast cancer. Visit www.morningcommutepodcast.com/HRPositiveBreast3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S18:E2 – Morning Commute Podcast: Embracing HER2-Low, Trop2-Directed, and Other Newer Approaches to HR-Positive Breast Cancer
November 30, 2023 16:59 - 30 minutes - 41.3 MBIn this podcast, our faculty take a look at some of the clinical data behind the newer treatment strategies for HR-positive breast cancer as well as how to address and manage some associated adverse events. Visit www.morningcommutepodcast.com/HRPositiveBreast2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S18:E1 – Morning Commute Podcast: An AKTor and Supporting Cast Take the Stage in HR+ Breast Cancer
November 30, 2023 16:58 - 23 minutes - 32.8 MBIn this podcast, our faculty discuss some newer treatment approaches for patients with HR-positive breast cancer including PI3K inhibition, AKT inhibition, and oral selective estrogen receptor down regulators. Visit www.morningcommutepodcast.com/HRPositiveBreast1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia
November 15, 2023 17:25 - 34 minutes - 47 MBFLT3-inhibitors, such as quizartinib, are changing the treatment paradigm for AML, in this podcast, our faculty take a look at the drug class, how they are used in AML, and how to manage any treatment-related adverse events. Visit www.morningcommutepodcast.com/aml4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib
November 15, 2023 17:24 - 31 minutes - 43.8 MBThe treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S17:E2 – Morning Commute Podcast: Treatment Options for Newly Diagnosed AML Patients
November 15, 2023 17:22 - 33 minutes - 46.3 MBIn this podcast our faculty discuss the latest treatment options for AML that target FLT3 mutations: midostaurin, gilteritinib, and the new kid on the block, quizartinib. Visit www.morningcommutepodcast.com/aml2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S17:E1 – Morning Commute Podcast: The Molecular Landscape of FLT3 Mutations in AML
November 15, 2023 17:12 - 26 minutes - 36.4 MBOur faculty discuss the importance of biomarker testing for FLT3 and FLT3-ITD and the prognostic impact for these patients, especially now that there are therapies targeting these mutations. Visit www.morningcommutepodcast.com/aml1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S16:E3 – Oncology Morning Commute: Sequencing Therapies in Endometrial Cancer Beyond the First-line Setting
July 26, 2023 01:10 - 23 minutes - 32 MBIn this podcast of our three-part series, our faculty continue their discussion on the treatment of endometrial cancer, this time looking at some of the key data on combination therapies as well as associated adverse events and how to handle them. Visit www.MorningCommutePodcast.com/Endometrial5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S16:E2 – Oncology Morning Commute: Is Immunotherapy Replacing Chemo in the First-Line Treatment Setting for Endometrial Cancer?
December 31, 2022 02:05 - 26 minutes - 36.1 MBIn this episode of our three-part series on endometrial cancer, our faculty continue their discussion by turning to some of the ongoing, and some may say groundbreaking, clinical trials for the use of immunotherapies in the first-line setting. Visit www.MorningCommutePodcast.com/Endometrial4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S16:E1 – Oncology Morning Commute: Understanding the Heterogeneity of Endometrial Cancer
December 31, 2022 02:00 - 25 minutes - 34.8 MBIn this podcast, our faculty discuss the heterogeneity of endometrial cancer and its four molecular classifications. How do these classifications help determine patient treatment plans? Visit www.MorningCommutePodcast.com/Endometrial3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S15:E3 – Oncology Morning Commute: HER2+ CRC Therapies in Clinical Practice
December 23, 2022 08:03 - 26 minutes - 36.4 MBIn this final podcast of our 3-part series, our faculty take their discussion of metastatic colorectal cancer and HER2-targeted therapies to the clinical level and share some patient cases. You don't want to miss these clinical pearls. Visit http://www.MorningCommutePodcast.com/CRC3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S15:E2 – Oncology Morning Commute: Emerging Data on HER2-Positive Colorectal Cancer Therapies
December 23, 2022 08:02 - 25 minutes - 35.2 MBIn this podcast, our faculty discuss HER2-positive colorectal cancer. HER2 has long been associated as a biomarker and treatment target for breast cancer, but now it is also a target in some colorectal cancers. Dr. John Marshall and Dr. Sunni Kim take a look at some of the recent clinical data on the investigational therapies targeting HER2-positive colorectal cancer. Visit http://www.MorningCommutePodcast.com/CRC2 to view the activity and CME/CE information, download the transcript, and co...
S15:E1 – Oncology Morning Commute: Recognition of Actionable Biomarkers in Colorectal Cancer
December 23, 2022 08:01 - 24 minutes - 33.8 MBIn this first podcast of our three-part series, our faculty discuss biomarkers for colorectal cancer including HER2. Are you aware of the current guideline recommendations for biomarker testing in colorectal cancer? Visit http://www.MorningCommutePodcast.com/CRC1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S14:E3 – Oncology Morning Commute: How Can Physicians Use Best Clinical Judgment to Determine Core Drivers for Cancer Screening?
December 22, 2022 11:03 - 22 minutes - 31.3 MBIn this final podcast of our 3-part series, our faculty continue their discussion on multicancer early detection tests, this time turning to how to incorporate these tests into clinical practice. Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S14:E2 – Oncology Morning Commute: A Review of the Science Behind Multicancer Early Detection Tests
December 22, 2022 08:02 - 24 minutes - 33.6 MBIn the second episode of our podcast series on early cancer detection, our faculty take a closer look at multicancer early detection tests and the groundbreaking PATHFINDER study that so far is showing impressive data. Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S14:E1 – Oncology Morning Commute: New Approaches to Testing Patients for Cancer
December 22, 2022 08:01 - 37.6 MBIn this podcast, our faculty discuss new methods of detecting cancer, including liquid biopsy and blood based, multicancer early detection tests. Can one blood sample provide accurate screening for many cancers? Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S13:E3 – Oncology Morning Commute: What’s Next in Using PARP Inhibitors for Patients With Ovarian Cancer?
December 16, 2022 04:15 - 29 minutes - 40.3 MBIn this final podcast of our three-part series, our faculty look at some of the latest findings on PARP inhibitors as well as what is on the horizon. They also tackle the topic of disparities in care for patients with ovarian cancer and how clinical trials can address this. Visit http://www.MorningCommutePodcast.com/OvarianCancer3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S13:E2 – Oncology Morning Commute: Managing Adverse Events That Occur With PARP Inhibition Therapies—What Your Patients Need to Know
December 16, 2022 04:11 - 40.8 MBIn this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for these therapies and how are adverse events managed for the best outcomes? Visit http://www.MorningCommutePodcast.com/OvarianCancer2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S13:E1 – Oncology Morning Commute: Patient Selection for Treatment With PARP Inhibitors in Ovarian Cancer
December 16, 2022 04:08 - 29 minutes - 40.7 MBWhat is the history behind the development of PARP inhibitors for the treatment of ovarian cancer and how have they influenced recent guideline changes regarding their use? Our faculty discuss this and more in the first podcast of the three-part series on PARP inhibitors and ovarian cancer. Visit http://www.MorningCommutePodcast.com/OvarianCancer1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S12:E3 – Oncology Morning Commute: Shifting Treatment Sequences in the Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape
November 23, 2022 02:49 - 22 minutes - 31.1 MBIn the final episode of our series, our faculty discuss the changing treatment landscape for diffuse large B-cell lymphoma. With more and more options, the paradigm is shifting and that's good news. Visit http://www.MorningCommutePodcast.com/BCell3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S12:E2 – Oncology Morning Commute: Antibody-Drug Conjugates and the Changing Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape
November 23, 2022 02:47 - 22 minutes - 30.2 MBWhat are the antibody-drug conjugate treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma? In this podcast our faculty look at key trial data as well as treatment management for this disease. Visit http://www.MorningCommutePodcast.com/BCell2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S12:E1 – Oncology Morning Commute: A Primer on B-Cell Targets in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
November 23, 2022 02:43 - 21 minutes - 29.7 MBIn this podcast, our faculty discuss relapsed/refractory diffuse large B-cell lymphoma, how refractory disease is defined, and the role of the new antibody-based therapies in relapsed/refractory disease. Visit http://www.MorningCommutePodcast.com/BCell1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S11:E6 – Oncology Morning Commute: Have I Got a Follicular Lymphoma Trial for You
October 01, 2022 01:37 - 23 minutes - 32.6 MBIn this final episode, our faculty discuss clinical trials that are in progress, the importance of the clinical trial process, and how they benefit patients and help move the needle on new and promising treatments. Visit http://www.MorningCommutePodcast.com/FL6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S11:E5 – Oncology Morning Commute: Safety First in Follicular Lymphoma
October 01, 2022 01:35 - 24 minutes - 34.2 MBIn this podcast, our faculty discuss the major classes of treatment for follicular lymphoma, including outcomes and managing the expected toxicities. Visit http://www.MorningCommutePodcast.com/FL5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S11:E4 – Oncology Morning Commute: Making the Case for Follicular Lymphoma Therapy
October 01, 2022 01:26 - 33.9 MBHow is the best way to select and sequence follicular lymphoma therapies? In this episode, our faculty discuss this and more. Visit http://www.MorningCommutePodcast.com/FL4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S11:E3 – Oncology Morning Commute: Follicular Lymphoma—Haven't We Met Before?
October 01, 2022 01:25 - 25 minutes - 34.8 MBIn our third podcast in this series, our faculty take a look at third-line treatment options for follicular lymphoma patients. Visit http://www.MorningCommutePodcast.com/FL3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S11:E2 – Oncology Morning Commute: What Can We Do About Early Relapsing Follicular Lymphoma?
October 01, 2022 01:20 - 26 minutes - 37 MBIn this second podcast of our series, our faculty continue their discussion of follicular lymphoma and its treatment, particularly for those patients who progress within the first 24 months, the progression of disease within 2 years (POD24). What is known about predictors of progression and what is the best path forward for these poor prognosis patients? Visit http://www.MorningCommutePodcast.com/FL2 to view the activity and CME/CE information, download the transcript, and complete the post...
S11:E1 – Oncology Morning Commute: Follicular Lymphoma: A New Patient Walks Into The Clinic
October 01, 2022 00:35 - 26 minutes - 35.9 MBWhat are the initial treatment strategies for the newly diagnosed patient with follicular lymphoma? Our faculty discuss this and more in this first episode of our series on follicular lymphoma. Visit www.MorningCommutePodcast.com/FL1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S9:E2 – Oncology Journal Club: How Covid Treatment Advances are Helping CLL Patients
July 25, 2022 16:36 - 41.4 MBThere is some good news for preventing and treating Covid in patients with chronic lymphocytic leukemia (CLL). New treatment advances allow clinicians to have a more balanced focus on CLL standards of care with Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib and anti-CD20 treatments such as rituximab, and not as much worry about Covid. Visit journalclubpodcasts.com/CLLCovid2 to view the activity and CME/CE information, download the transcript, and complete the post-test and eval...
S10:E5 – Oncology Morning Commute: Toxicity Risks and the New-Generation Treatments for CML
May 15, 2022 21:00 - 14 minutes - 19.5 MBAs with any treatment, toxicities can be a concern. Our faculty return to discuss toxicities with third-generation tyrosine kinase inhibitors. How can these toxicities be mitigated? How can you maximize benefit and minimize risks? Visit http://www.morningcommutepodcast.com/CML5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S10:E4 – Oncology Morning Commute: Keeping Watch—Treatment Response in CML
May 15, 2022 20:00 - 15 minutes - 21.1 MBWhat are the treatment response benchmarks when treating chronic myeloid leukemia and when, if ever, should therapies be switched? Moreover, how do you know if they are working? Our faculty discuss these questions and more. Visit http://www.morningcommutepodcast.com/CML4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S10:E3 – Oncology Morning Commute: Dialing Down—Optimizing Third-Generation Treatments for CML
May 15, 2022 19:00 - 14 minutes - 20.6 MBWhen treating patients with chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors, what is the optimal dose? Our faculty discuss this as well as treatment duration and other considerations for using these third-generation therapies. Visit http://www.morningcommutepodcast.com/CML3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S10:E2 – Oncology Morning Commute: Targeting STAMP in CML
May 15, 2022 18:00 - 14 minutes - 20.5 MBIn this podcast our faculty return for a discussion of a new target for the treatment of chronic myeloid leukemia and the newest treatment on the block, asciminib. Visit http://www.morningcommutepodcast.com/CML2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S10:E1 – Oncology Morning Commute: Third-Line Treatment of CML
May 15, 2022 17:00 - 17 minutes - 23.6 MBThird-line treatment of chronic myeloid leukemia and in particular BCR-ABL1 tyrosine kinase inhibitors are the latest therapeutics in the clinician’s toolbox. In this podcast, our faculty discuss these treatments and which patients can derive the most benefit from them. Visit http://www.morningcommutepodcast.com/CML1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S9:E1 – Oncology Journal Club: Covid-19 and CLL Implications for Treatment Decision-Making
May 15, 2022 16:00 - 48.6 MBHow is the Covid-19 pandemic affecting patients with chronic lymphocytic leukemia (CLL)? Our faculty discuss several papers during this podcast that address the efficacy of CLL treatments, especially Bruton’s tyrosine kinase inhibitors, on CLL as well as vaccine response in the treatment decisions for this patient population. Visit http://www.journalclubpodcasts.com/CLLCovid1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to e...
S8:E3 – Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time?
March 28, 2022 16:30 - 18 minutes - 25.4 MBOur faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates as treatment for this disease. But are they ready for prime time? Visit http://morningcommutepodcast.com/nsclc6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S8:E2 – Oncology Morning Commute: PD-L1 Expression in NSCLC
March 28, 2022 16:20 - 17 minutes - 24.6 MBOur faculty takes a look at PD-L1 expression and immunotherapies. Who are the best candidates for these therapies? Who should not receive them? Visit http://morningcommutepodcast.com/nsclc5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S8:E1 – Oncology Morning Commute: Molecular Profiling in Non-Small Cell Lung Cancer
March 26, 2022 16:00 - 17 minutes - 24.4 MBOur faculty discuss molecular testing for non-small cell lung cancer (NSCLC). Should all patients with NSCLC be tested for biomarkers? Visit http://morningcommutepodcast.com/nsclc4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S7:E5 – Oncology Morning Commute: Clinical Trials—Ensuring Inclusivity
March 15, 2022 17:50 - 14 minutes - 19.9 MBIn this episode our faculty discuss clinical trials in oncology. Are they reflective of the general population of patients who will ultimately be affected by the trial outcomes? What are the factors that impact clinical trial demographics? Visit www.morningcommutepodcast.com/disparities5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S7:E4 – Oncology Morning Commute: Disparities in Care
March 15, 2022 17:40 - 13 minutes - 18.2 MBIn this episode, our faculty continues their discussion about disparities in oncology care. Is there a solution? How can being team-focused help patients in their cancer care journey? Visit www.morningcommutepodcast.com/disparities4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S7:E3 – Oncology Morning Commute: Addressing Bias in Patient Care
March 15, 2022 17:30 - 10 minutes - 14.6 MBHow does implicit bias impact patient care? What is unconscious bias and how can clinicians become more aware of their own biases is regard to patient care? Our faculty tackles these topics in this episode. Visit www.morningcommutepodcast.com/disparities3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S7:E2 – Oncology Morning Commute: Improving Equity in Healthcare
March 15, 2022 17:10 - 12 minutes - 17.2 MBIn this episode our faculty will focus on health equity. What causes health inequity? Is it lack of access to care, cancer screenings, early diagnoses? How does socioeconomic variables factor in? These questions and more will be discussed in this podcast. Visit www.morningcommutepodcast.com/disparities2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S7:E1 – Oncology Morning Commute: The Health Disparities Landscape
March 15, 2022 17:05 - 14 minutes - 20 MBIn this episode, our faculty discuss disparities in oncology care. What exactly are health disparities? What populations are most at risk for experiencing disparities in care? Visit www.morningcommutepodcast.com/disparities1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S6:E6 – Oncology Morning Commute: The Emerging Role for Antibody-Drug Conjugates in GI Cancers
February 28, 2022 23:00 - 22 minutes - 31 MBIn this podcast our faculty discuss gastrointestinal (GI) cancers and antibody-drug conjugates. How are these new therapies changing the landscape of GI cancer care? Visit www.morningcommutepodcast.com/solidtumors6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S6:E5 – Oncology Morning Commute: Targeted Therapies for Gastroesophageal and Colorectal Cancers
February 28, 2022 22:00 - 22 minutes - 30.5 MBHER2 expression in gastric/gastroesophageal junction and colorectal cancer potentially paves the way for the use of targeted therapies for these cancers. Our faculty discuss these important clinical developments. Visit www.morningcommutepodcast.com/solidtumors5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
S6:E4 – Oncology Morning Commute: Targeting HER2, HER3, and TROP2 in NSCLC
February 28, 2022 21:00 - 26 minutes - 36.9 MBOur faculty continue their discussion on antibody-drug conjugates and look at some of the promising trials in NSCLC for these promising therapies. Visit www.morningcommutepodcast.com/solidtumors4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
S6:E3 – Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time?
February 28, 2022 20:00 - 36.2 MBOur faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates as treatment for this disease. But are they ready for prime time? Visit www.morningcommutepodcast.com/solidtumors3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit